Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at November 2024 Investor Conferences Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Key Takeaway: Insmed Incorporated announced its participation in upcoming investor conferences, which will be available via live webcasts on their website. The company continues to focus on delivering innovative therapies for serious diseases and has a robust pipeline that includes approved and investigational medicines. Insmed is recognized as a leading employer in the biopharmaceutical sector and is dedicated to patient-centric drug development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is advancing a diverse portfolio of approved and investigative medicines.
  • The company has been recognized as one of the best employers in the biopharmaceutical industry.
  • Insmed's therapies address serious diseases, improving patient outcomes.

Full Press Release Details

BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Webcasts will be archived for a period of 30 days following the conclusion of the live events.
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey , Insmed has offices and research locations throughout the United States , Europe , and Japan . Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations (646) 812-4030 [email protected]
Michael V. Morabito , Ph.D. Director, Investor Relations (917) 936-8430 [email protected]
Gianna De Palma Manager, Investor Relations (973) 886-2236 [email protected]
Mandy Fahey Vice President, Corporate Communications (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What is Insmed Incorporated known for?

Insmed Incorporated focuses on delivering innovative therapies for serious diseases.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

Which conditions does Insmed's portfolio address?

Insmed's portfolio primarily targets pulmonary and inflammatory conditions.

How can I access Insmed's investor event webcasts?

Webcasts are available on Insmed's investor relations website for 30 days.

What recognition has Insmed received as an employer?

Insmed has been recognized as a top employer in the biopharma industry for years.

Last updated: Nov 6, 2024